RJA
NVO

Raymond James & Associates’s Novo Nordisk NVO Stock Holding History

Raymond James & Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,500
Closed -$368K – 3997
2023
Q4 		$368K Sell
3,500
-5,300
-60% -$524K ﹤0.01% 3151
2023
Q3 		$845K Buy
+8,800
New +$775K ﹤0.01% 2576
2023
Q2 		– Sell
-13,000
Closed -$910K – 3928
2023
Q1 		$910K Buy
+13,000
New +$922K ﹤0.01% 2508

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James & Associates's NVO Position: Q3 2024 in Review

Raymond James & Associates increased its Novo Nordisk (NVO) stake by 0.56% in Q3 2024, buying an estimated $2.62M and bringing the position to 3,526,821 shares worth $420M. The position accounts for 0.26% of the portfolio, ranked #61.

Raymond James & Associates first reported a position in NVO in Q2 2013 and has held it in 46 quarters since. The position peaked at $501M in Q2 2024. 1,785 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Raymond James & Associates held 3,526,821 shares of Novo Nordisk worth $420M as of Q3 2024.
  • Raymond James & Associates bought 19,623 Novo Nordisk shares in Q3 2024, an estimated $2.62M.
  • Novo Nordisk made up 0.26% of Raymond James & Associates's portfolio in Q3 2024, its #61 holding.
  • Raymond James & Associates first reported a position in Novo Nordisk in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Novo Nordisk position peaked at $501M in Q2 2024.
  • 1,785 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.